Semaglutide—a new treatment for obesity-related heart failure with preserved ejection fraction?

Heart failure with preserved ejection fraction accounts for nearly half of heart failure cases.1 Despite the heterogeneous nature of the disease, a uniform treatment has predominantly been used, which has shown benefits in heart failure with reduced ejection fraction but is less efficacious in heart failure with preserved ejection fraction. SGLT2 inhibitors are the only disease-modifying drugs for heart failure with preserved ejection fraction.2 Phenotypic characterisation of the disease is essential to provide optimal, targeted therapies.